Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital

Similar documents
SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre

European Heart Journal 2015 doi: /eurheartj/ehv320

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Pharmacy STROKE. Anne Kinnear Lead Pharmacist NHS Lothian. Educational Solutions for Workforce Development

Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved

Best Medical Therapy for asymptomatic carotid disease

Alan Barber. Professor of Clinical Neurology University of Auckland

Page 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem

CV Update Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet 27/01/09

Basics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY

Know Your Number Aggregate Report Single Analysis Compared to National Averages

ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised

Do Not Cite. Draft for Work Group Review.

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Coronary Heart Disease

Dr Ben Turner. Consultant Neurologist and Honorary Senior Lecturer Barts and The London NHS Trust London Bridge Hospital

CONCISE GUIDE National Clinical Guidelines for Stroke 2nd Edition

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION

stroke.org.uk Atrial Fibrillation Reducing your risk of stroke

Asif Serajian DO FACC FSCAI

Epidemiology and Prevention of Stroke

Alan Barber. Professor of Clinical Neurology University of Auckland

STROKE UPDATE ANTHEA PARRY MAY 2010

2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate

14/15 Threshold 15/16 Points 15/16. Points. Retired Replaced by NM82/AF007. Replacement NO CHANGE

Primary Prevention of Stroke

Commissioning for value focus pack

The contractor establishes and maintains a register of patients with AF

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Stroke: Prevention is the Best Medicine

Retrospective Study on the Safety and Efficacy of Clopidogrel in the Treatment of Acute Cerebral Infarction

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016

Coronary Artery Disease Clinical Practice Guidelines

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

Vascular Diseases. Overview: Selected Slides

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Long-Term Care Updates

Atrial fibrillation: current approaches to management

Cardiovascular risk reduction in diabetes Lipids (NICE CG181)

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.

Mohammad Zubaid, MB, ChB, FRCPC, FACC

Diabetes Mellitus: A Cardiovascular Disease

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Clinical guideline for the management of atrial fibrillation

Guidelines on cardiovascular risk assessment and management

Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia

Antithrombotic Therapy in Patients with Atrial Fibrillation

ASPIRIN AND VASCULAR DISEASE

Results from RE-LY and RELY-ABLE

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

Treatment strategy decision tree

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

Cost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib

Guideline scope Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (update)

Aspirin for cardiovascular disease prevention

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Practice-Level Executive Summary Report

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Coronary heart disease and stroke

Prof. Jindřich Špinar, MD

10/21/2014. Disclosures. Introduction. Reasons for the Decline in Stroke Mortality: Implications for Hypertension and Risk Factor Management

Atrial Fibrillation Cases. Dr Paul Broadhurst Consultant Cardiologist

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Investor Conference Call

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation

Subject Expert. Michelle Whaley MSN, CNS, CCNS, ANVP-BC Swedish Medical Center Englewood, CO

1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown

ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease

Quality Payment Program: Cardiology Specialty Measure Set

Supplementary Online Content

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39

Trends and Variations in General Medical Services Indicators for Coronary Heart Disease: Analysis of QRESEARCH Data

The Clinical Unmet need in the patient with Diabetes and ACS

Atrial fibrillation. Understanding NICE guidance

Geriatric Grand Rounds

Restart or stop antithrombotics after intracerebral haemorrhage (ICH)?

Real-World Insights from GARFIELD-AF Registry Presented at ESC Congress 2017

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Section Editor Scott E Kasner, MD

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

SECONDARY PREVENTION OF CORONARY HEART DISEASE AND ISCHAEMIC STROKE/TIA

Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?

Current Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine

Transcription:

Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital

Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke have another stroke within the first 30 days 9% in the first 6 months and 10 16% within a year. After the first year, the average annual risk of recurrent stroke for the next 4 years falls to about 5%

Modifiable risk factors

Modifiable risk factors High cholesterol High blood pressure Obesity Excessive alcohol Smoking Poor diet Lack of physical activity Illicit drug use

Non-Modifiable risk factors

Non-Modifiable risk factors Age: most powerful independent risk factor Ethnicity: increased stroke in Black African/Caribbean populations, similarly Chinese and Japanese populations have increased risk of haemorrhagic stroke Heredity or family history: increased risk if a first-degree relative has had coronary heart disease or stroke before the age of 55 years (for a male relative) or 65 years (for a female relative) Previous history of TIA and/or stroke Clotting disorders Congenital cardiac disorders

Stroke and ethnicity in London (Gulli et al 2016) White Black Age 74.8 65.1 Hypertension 72.9% 83.9% Diabetes 18.3% 40.8% Smoking 61.8% 40.4% Heart disease 22.5% 12.4% AF 32.9% 12.7%

High blood pressure High blood pressure is the most important treatable and causal risk factor for stroke A meta-analysis of data from nine randomized controlled trials on the effects of blood pressure lowering drugs (n= 6752) relative risk reduction of recurrent stroke of 29% (95% confidence interval: 5 47%) (Gueyffier et al, 1997)

BP Control Optimal target BP for patients with established cardiovascular disease is <135/85mmHg Benefits: 33-46% reduction in fatal or disabling stroke 50-76% reduction in the risk of cerebral haemorrhage 38-42% reduction in non-fatal myocardial infarction All benefits achieved against a background of standard care that included antiplatelet and antihypertensive therapy

Antiplatelet agents

Antiplatelet agents Clopidogrel better at stroke reduction than aspirin 8.7% relative risk reduction (CAPRIE trial) Clopidogrel plus aspirin increases risk of serious bleeding by 2.5 times with no increased benefit (MATCH and CURE trials)

Anti-Platelet Agents All patients should be prescribed aspirin 300mg daily, initiated within 48 hours of acute ischaemic stroke and continued for up to 14 days Clopidogrel monotherapy is the preferred secondary prevention strategy following stroke or TIA Where clopidogrel cannot be used due to intolerance, aspirin and dipyridamole should be used in combination Proton pump inhibitor only when there is dyspepsia or other significant risk of gastrointestinal bleeding

Classification of AF Terminology Clinical features Pattern Initial event (first detected episode) Symptomatic Asymptomatic Onset unknown May or may nor reoccur Paroxysmal Spontaneous termination <7 days and most often <48 hours Persistent Permanent ( accepted ) Not self-terminating Lasting >7 days or prior cardioversion Not terminated Terminated but relapsed No cardioversion attempt Recurrent Recurrent Established

Anticoagulation NICE 2008 Anticoagulation should be recommended in every patient with persistent or paroxysmal atrial fibrillation (15% of all strokes) (valvular and nonvalvular) unless contraindicated Reduces the relative risk of stroke by up to 70% Antiocoagulation should not be started stroke until brain imaging has excluded haemorrhage and not usually until 14 days of ischaemic stroke Anticoagulation should not be used for patients in sinus rhythm unless a major cardiac source of embolism has been identified

Risk scoring tools

Smoking Smoking has been shown to be associated with a doubling of risk among smokers compared with non smokers 12.5 million people smoke Risk of stroke is 2 to 4 times the risk in non smokers 5 yrs after stopping smoking the risk is reduced to that of a non smoker Ensure follow up information given

Lipid control All patients who have had an ischaemic stroke or TIA should be treated with a statin drug unless contraindicated to ensure: total cholesterol <4.0 mmol/l, LDL cholesterol <2.0 mmol/l. Treatment with statin therapy should be avoided or used with caution in haemorrhagic stroke, particularly those with inadequately controlled hypertension. Ensure patients are informed of important potential side effects!

Alcohol There is strong evidence that high alcohol indicate is a risk factors for stroke 27% of men and 17% of women consume more than the recommended weekly limits of alcohol (21 units for men and 14 units for women) There is a strong relation between heavy drinking and stroke: male drinkers of over 35 units a week have double the risk of mortality from stroke than non drinkers

Alcohol how many units?

Alcohol

Obesity and exercise Obesity, defined as a body mass index (BMI) of >30 kg/m2, has been established as an independent risk factor for CHD and premature mortality From studies on physical activity and stroke, moderately or highly active individuals had a 27% lower risk of stroke incidence or mortality than did low-activity individuals There is little evidence on exercise in secondary prevention

Cycle of change

Cycle of change In contemplation the person is ambivalent - they are in two minds about what they want to do. Sometimes they feel the need to change but not always. In action the person is preparing and planning for change. When they are ready the decision to change is made and it becomes all consuming. In maintenance the change has been integrated into the person's life. Some support may still be needed through this stage. In maintenance lasting change is learned, practised and becomes possible. When we are able to maintain what we have achieved we exit the cycle entirely.